Arcturus Therapeutics Holdings Inc (ARCT) is a biopharmaceutical company that focuses on developing RNA medicines, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotide (ASO) therapeutics. ARCT is based in San Diego, California and was founded in 2013.
Some key points about ARCT:
ARCT's proprietary mRNA therapeutics platform is called "LUNAR", which stands for "Lipid-enabled and Unlocked Nucleic Acid modified RNA".
The company is primarily focused on developing RNA medicines for the treatment of rare diseases, including cystic fibrosis, ornithine transcarbamylase deficiency (OTCD), and glycogen storage disease type 3 (GSD3).
ARCT has also developed a COVID-19 vaccine candidate based on its mRNA platform, which it is developing in partnership with Singapore's Duke-NUS Medical School.
The company has partnerships with other biopharmaceutical companies, including Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) and Ultragenyx Pharmaceutical, to develop RNA therapeutics.
In December 2020, ARCT announced that it had entered into an agreement with Israel's Ministry of Health to supply its COVID-19 vaccine candidate to the country's population, pending regulatory approval.
As of February 2023, ARCT's stock is listed on the NASDAQ exchange with a market capitalization of approximately $2.2 billion.
|
